Schlieren and St. Gallen, Switzerland, April 2, 2020. The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer diagnosis, is made available by the Center for Laboratory Medicine St. Gallen (Zentrum für Labormedizin St. Gallen, ZLM).
”Proclarix is an important new tool for physicians to improve the prostate cancer diagnostics in men with elevated PSA and we are excited to be the first laboratory worldwide to offer this innovation”, said Prof. Dr. med. Wolfgang Korte, CEO of ZLM. “Further information on how Proclarix can be ordered is available on our website”.
“We are delighted to have the ZLM as a partner and expect that our collaboration will help men suspected to have prostate cancer”, said Christian Brühlmann, CBO of Proteomedix. “Recently published clinical evidence of Proclarix in BJUI Compass clearly shows Proclarix’ potential in this challenging patient population and that the test can help to reduce the number of biopsies avoiding invasive procedures, anxiety, discomfort, pain and complications”.
Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitroassays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
The Center for Laboratory Medicine St. Gallen is an ISO/IEC17025 accredited clinical laboratory in St. Gallen, Switzerland. The ZLM delivers high quality diagnostic services to the Cantonal Hospital St. Gallen, public hospitals and a large number of general practitioners and urologists in Eastern Switzerland as well specialized laboratory research services to research groups worldwide. The ZLM has more than 200 motivated and highly trained staff members and a longstanding expertise in the areas of clinical chemistry, hematology, immunology, microbiology, and genetics with a menu of more than 1500 tests. Visit www.zlmsg.ch for more information. To secure adequate logistics for Proclarix® testing, please contact us via firstname.lastname@example.org.
For questions on laboratory services, please contact:
Prof. Dr. med. Wolfgang Korte, CEO, ZLM
+41 58 580 92 00
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the market early 2020. Proteomedix is located in the Bio-Technopark of Schlieren, Switzerland. For more information, visit www.proteomedix.com.
For further details, please contact:
Christian Brühlmann, CBO
+41 44 733 40 90